TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02193672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Fluciclatide
Description: \[18F\] Fluciclatide given by vein before PET/CT scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Description: PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
Study: NCT02145312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
Study: NCT01167959

Intervention type: PROCEDURE
Intervention: Roux en Y gastric bypass and lap. gastric banding
Description: Standard RYGB and LAGB procedures

Intervention type: BEHAVIORAL
Intervention: Prodimed dietary intervention
Description: 3 months of using the prodimed diet
Study: NCT01962480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The hernia gap is sutured intracorporally
Description: The hernia gab is closed with non-absorbable suture (Ethibond Excel 2-0, Ethicon, Johnson \& Johnson©) performed by an intracorporally interrupted sutured technique using an Auto Suture© Endo-Slide knot-tying instrument. The stitches are placed with a distance of 0.5 - 1 cm from the fascial edges and with a distance of 0.5-1 cm. between the stitches, performed under a 6-8 mmHg intrabdominal pressure.
Study: NCT02621918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Study: NCT00567047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study: NCT04168190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax™23
Description: Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax™23
Description: Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Study: NCT02193672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Phone call to participants by study staff about 24 hours after each PET/CT is performed.
Study: NCT02596685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Undergo bronchoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Undergo bronchoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Undergo bronchoscopy
Study: NCT01758432

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Apixaban
Study: NCT02596685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Undergo bronchoscopy
Study: NCT01758432

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Apixaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Apixaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Apixaban

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00901901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400 mg twice daily
Study: NCT02596685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Given nicotine-free and flavor-free electronic cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04694742

Intervention type: OTHER
Intervention: data collecting
Description: Within 24h from ICU admission, the ventilatory efficiency will be assessed by the following Ventilatory Ratio equation:~Ventilatory Ratio = \[minute ventilation (ml/min) × PaCO2 (mm Hg)\]/(predicted body weight × 100 × 37.5).~Where PaCO2 is the partial pressure of carbon dioxide in mmHg in the arterial blood.~Tha quasi-static compliance will be calculated according to the equation:~C=Tidal Volume/(Paw plateau - PEEP total)~where Paw plateau is the airway pressure measured during 4 seconds of inspiratory pause, PEEP total is the airway pressure measured during 4 seconds of expiratory pause.~In the same time frame, complete blood count, d-dimer, sequential organ failure assessment score, blood gas analysis, haemodynamic and ventilatory parameters will be collected.
Study: NCT02048605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-social CBT based training
Description: Number of Sessions: 9x Content: cognitive behavioral group-training-program to reduce stress and augment quality of life.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unspecific group training
Description: Number of sessions: 9x Content: Music or Art Therapy Nutrition Education around Food Functional Movement Physical Activity Group discussion
Study: NCT03909412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.
Study: NCT02994992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987516
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-100)
Study: NCT00901901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Description: Erlotinib 150 mg once daily
Study: NCT02994992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT01434667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APOE genotype and Alzheimer's disease risk disclosure
Description: Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
Study: NCT00901901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching erlotinib placebo 150 mg once daily
Study: NCT01434667

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alzheimer's disease risk disclosure
Description: Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
Study: NCT02650674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A: NP-0148
Description: Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose solution
Description: Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B: NP-0149
Description: Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C: NP-0150
Description: Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D: NP-0151
Description: Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E: NP-0152
Description: Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
Study: NCT02664844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study: NCT03909412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg IV/PO to be administered as a premedication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg IV/PO to be administered as a premedication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg IV/PO to be administered as a premedication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg IV/PO to be administered as a premedication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg IV/PO to be administered as a premedication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg IV/PO to be administered as a premedication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
Study: NCT03272399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet/nutrition intervention
Description: The intervention will be administered through food products rather than dietary supplements
Study: NCT03909412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
Study: NCT01303952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
Study: NCT03653234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TV-based Assistive Integrated Service
Description: TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice.
Study: NCT01834599

Intervention type: DEVICE
Intervention: cerebral oximetry
Description: tissue saturation measurement in pregnant women
Study: NCT02741986

Intervention type: OTHER
Intervention: Risk estimation
Description: Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study.
Study: NCT02596685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00803738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terconazole Vaginal Suppository
Description: Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terazol Vaginal Suppository
Description: Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
Study: NCT01583114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perindopril
Description: form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
Study: NCT01670669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: 0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
Study: NCT01282385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
Study: NCT03516175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow transnasal oxygen
Description: High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre oxygenation using tight fitting facemask
Description: 100% oxygen via a tight fitting facemask
Study: NCT03759639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IB1001
Description: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
Study: NCT03492502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Fecal Microbiota Transplantation
Description: Consenting allo- SCT patients with acute steroid-resistant GI-related GVHD grade III-IV will receive autologous FMT by nasogastric tube. Standardized stool suspension will be given once a day for two consecutive days.In order to prevent aspiration, patients will be kept in a 45ᵒ upright position for four hours. Participants will fast the night before and be treated with proton pump inhibitors prior to each FMT.~In cases where complete response was not obtained within 7 days after autologous FMT, patients may be eligible for another trail of autologous FMT or to switch to other pharmacological interventions. Stool samples will be collected before and after the intervention for microbial analyses.
Study: NCT00613548

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG alone
Description: CABG alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG + Mitral repair
Description: CABG + Mitral repair
Study: NCT02596685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02970136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick Swab
Description: OraQuick for oral fluid HIV antibody testing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test
Description: Fecal Immunochemical stool test specific for human hemoglobin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick Fingerstick
Description: Patients will be tested for Hepatitis C infection using a fingerstick

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Screening Tests
Description: Patients will be navigated to a local health center for standard screening tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV Self-Sampling Test
Description: Patients will be using swab to check for HPV infection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Screening Tests
Description: Patients will provided screening tests and instructed by Community Health Worker on how to perform home screening tests
Study: NCT02596685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03272399

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet/nutrition intervention
Description: The intervention will be administered through food products rather than dietary supplements
Study: NCT04214769

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiometry and tympanometry, vHIT, VEMP, ENG
Description: Diagnostic tests
Study: NCT02646137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization (TACE)
Description: TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
Study: NCT00976495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Tablets, Oral, 25 mg, once daily, 12 weeks
Study: NCT01886729

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Study: NCT00822367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucerna; Ensure; SlimFast
Description: Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
Study: NCT04414826

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Alone (MO) Intervention
Description: Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness and non-reactivity skills.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness Alone (MO) Intervention
Description: Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness and non-reactivity skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness + Compassion Intervention (MC)
Description: Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness, non-reactivity, and compassion skills.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness + Compassion Intervention (MC)
Description: Participants will receive a one-session, hour-long telehealth intervention emphasizing awareness, non-reactivity, and compassion skills.
Study: NCT00830154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pagoclone
Description: 0.30 mg BID, 0.60 mg BID